Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00205647
Recruitment Status :
First Posted : September 20, 2005
Last Update Posted : November 6, 2017
Wake Forest University
Information provided by (Responsible Party):
Wake Forest University Health Sciences ( Wake Forest University )
This is a randonmized, masked, placebo-controlled parallel group, clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine (NAC) and placebo on patient safety and on physical and transport properties of expectorated sputum. Patient sumptoms, quality of life and exacerbation will also be followed as well as pulmonary function testing and functional exercise capacity. We hypothesized that a prolongeed course of oral NAC favorably affects the morbidity of chronic bronchitis, particularly the incidence of acute exacerbations.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Smokers (past or current,20 pack years) with diagnosis of chronic bronchitis
expectorate sputum daily
FEV1 of 40-70%
understand and fill out questionnaire daily
other investigational within 30 days
change in smoking habit within 6 months
pulmonary diagnosis other that chronic bronchitis
significant renal, cardiac, hepatic or endocrine diseases
psychiatric disorder or evidence of alcoholism or drug abuse within year